SAL007 was approved by FDA in February 2020 for its first clinical trial. The head clinical researchinstitute of clinical phase I in US is Cleveland Clinic, and currently thetrial is recruiting participants. The participants have achieved very good results.
SAL007 Phase I Clinical Research Center
